Comparative mortality risk in adult patients with schizophrenia, depression, bipolar disorder, anxiety disorders, and attention-deficit/hyperactivity disorder participating in psychopharmacology clinical trials

• Published in: JAMA psychiatry (Chicago, Ill.) Vol. 70; no. 10; p. 1091
• Main Authors: Khan, Arif, Faucett, James, Morrison, Shaneta, Brown, Walter A
• Format: Journal Article
• Language: English
• Published: United States 01.10.2013
• Subjects: Adult; Age Factors; Aged; Clinical Trials as Topic - adverse effects; Female; Humans; Male; Mental Disorders - mortality; Middle Aged; Psychotropic Drugs - adverse effects; Risk Factors; Suicide - statistics & numerical data; United States - epidemiology; United States

There is concern that increased mortality risk among patients with psychiatric illness may be worsened by psychopharmacological agents. To assess mortality risk among adult patients with a diagnosis of schizophrenia, depression, bipolar disorder, anxiety disorders, or attention-deficit/hyperactivity...